Pictet Asset Management Holding SA Purchases 140,605 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Pictet Asset Management Holding SA raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 13.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,157,452 shares of the company's stock after purchasing an additional 140,605 shares during the quarter. Pictet Asset Management Holding SA owned 1.25% of NewAmsterdam Pharma worth $29,747,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of NewAmsterdam Pharma by 172.8% during the fourth quarter. JPMorgan Chase & Co. now owns 60,977 shares of the company's stock valued at $1,567,000 after buying an additional 38,626 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in NewAmsterdam Pharma during the 4th quarter worth $154,000. American Century Companies Inc. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $8,907,000. DCF Advisers LLC raised its holdings in shares of NewAmsterdam Pharma by 162.9% in the fourth quarter. DCF Advisers LLC now owns 89,400 shares of the company's stock valued at $2,298,000 after purchasing an additional 55,400 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in NewAmsterdam Pharma during the fourth quarter worth about $276,000. 89.89% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James N. Topper purchased 4,005 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average cost of $21.02 per share, with a total value of $84,185.10. Following the purchase, the director now directly owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This trade represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

Remove Ads

NewAmsterdam Pharma Stock Down 10.2 %

NAMS traded down $2.09 on Tuesday, hitting $18.38. The company's stock had a trading volume of 2,585,205 shares, compared to its average volume of 545,463. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The firm has a market cap of $2.02 billion, a P/E ratio of -7.07 and a beta of -0.04. The company's 50 day simple moving average is $21.50 and its 200-day simple moving average is $21.32.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. Equities analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. HC Wainwright restated a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Needham & Company LLC lowered their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.